Eisai transfers its Research Triangle Park Campus to Biogen

17 July 2015

The US subsidiary of Japanese drug major Eisai (TYO: 4523) has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP) manufacturing campus to biotech firm Biogen (Nasdaq: BIIB).

This arrangement expands on the capacity-sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013. No financial terms of the transaction were revealed.

Under this new agreement, Biogen will continue to manufacture oral solid-dose products for Eisai. In addition, Eisai has entered into a new manufacturing agreement whereby Biogen will manufacture Eisai's parenteral products. Among these, Biogen will produce for Eisai the Japanese firm’s AcipHex/Pariet (rabeprazole), Aricept (donepezil), Banzel (rufinamide), Lunesta (eszopiclone) and Halaven (eribulin mesylate).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK